Alignment with FDA obtained on study design to advance two Ph 3 trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F] FAPI-74
“The successful FDA engagement brings us closer to making FAPI a reality for patients in areas of unmet need across multiple tumor types”, said Sherly Mosessian, Ph.D., Chief Scientific Officer of SOFIE Biosciences. “Unlike conventional imaging and FDG PET, FAPI targets cancer-associated fibroblasts in the tumor microenvironment, giving us a key target for determination of disease. FAPI PET has tremendous potential in many oncologic and non-oncologic diseases. We are looking forward to focusing our initial efforts on the cancers of the GI tract, specifically gastroesophageal cancers and PDAC, where we see tremendous unmet need that can be successfully addressed with FAPI PET. We are excited to advance into Phase 3 and continue building the evidence that will establish FAPI PET/CT as a transformative tool in precision oncology.”
Share:
More News
“This research collaboration with AbCellera directly aligns with Jazz’s rare disease strategy, expanding our focus on GI cancers and building on our existing expertise in oncology,” said Josh Allen, Ph.D., chief scientific officer, oncology, Jazz Pharmaceuticals. “We look forward to collaborating with AbCellera to progress potential best-in-class TCE multispecific antibodies
AIM Chief Executive Officer Thomas K. Equels stated: “AIM hopes to utilize the exploratory biomarker data generated through DURIPANC to design a Phase 3 study involving Ampligen in the treatment of pancreatic cancer. We are particularly interested in evaluating whether specific biomarkers may help to identify ‘super-responder’ patient subsets most
“We are committed to improving the treatment of glioblastoma and are grateful to our investigators and the patients and families who made the TRIDENT trial possible,” said Uri Weinberg, MD, PhD, Chief Medical and Innovation Officer, Novocure. “The study did not meet its primary endpoint, but the results from TRIDENT
“Fast Track Designation is a valuable step forward for givastomig and for patients with first-line HER2-negative metastatic gastric cancer,” said Phillip Dennis, MD, PhD, Chief Medical Officer of NovaBridge. “Phase 1b results demonstrate robust efficacy and favorable overall tolerability in combination with immunochemotherapy. Responses were deep and durable across a